BiotechTube
Curio Bioscience

Curio Bioscience

Palo Alto, United States· Est.
curiobioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.7M

Overview

Curio Bioscience, founded in 2020 and based in Palo Alto, is a developer of spatial omics technologies now operating under Takara Bio USA. Its core platforms, Trekker and Seeker, offer single-cell and whole-transcriptome spatial mapping, respectively, designed for ease of use without requiring new capital equipment. The company targets the rapidly growing spatial biology market, serving academic, biopharma, and clinical researchers seeking to understand tissue architecture in health and disease. Its acquisition by Takara provides commercial scale and global reach.

Genetics & Genomics

Technology Platform

Spatial transcriptomics platforms (Trekker and Seeker) based on Slide-tag and Slide-seq technologies for high-resolution, single-cell, and whole-transcriptome mapping of gene expression in tissue samples without requiring dedicated capital equipment.

Funding History

1
Total raised:$6.7M
Seed$6.7M

Opportunities

The massive and growing spatial biology market, particularly among researchers seeking high-resolution data without major capital investment, presents a major opportunity.
Integration into Takara Bio's global commercial network accelerates market access and scale.
The technology's precision also opens a long-term pathway into clinical diagnostics and biomarker discovery for biopharma partners.

Risk Factors

Faces intense competition from well-established, well-funded players in spatial omics with broader portfolios and installed instrument bases.
The rapid pace of technological innovation risks obsolescence.
Success depends on effective commercial execution and integration within the larger Takara Bio organization.

Competitive Landscape

Operates in the highly competitive spatial transcriptomics market against major players like 10x Genomics (Visium), NanoString Technologies (GeoMx, CosMx), and Vizgen (MERSCOPE). Curio's key differentiation is its instrument-free, high-resolution approach that plugs into existing sequencing workflows, targeting cost- and complexity-sensitive researchers versus competitors who often rely on proprietary imaging or instrumentation.

More companies in Diagnostics & Precision Medicine →More companies in United States →